Loading...
•
Dec 31, 2020
Mimedx Q4 2020 Earnings Report
MiMedx experienced a decrease in net sales but an increase in gross margin, while also incurring a net loss due to investigation, restatement, and related expenses.
Key Takeaways
MiMedx reported Q4 net sales of $68.5 million and a net loss of $16.6 million. The company's adjusted EBITDA was $10.3 million. Full year net sales were $248.2 million with a net loss of $49.3 million.
Fourth quarter net sales reached $68.5 million.
Full year net sales amounted to $248.2 million.
The company reported a fourth quarter net loss of $16.6 million.
Adjusted EBITDA for the fourth quarter was $10.3 million.
Forward Guidance
MiMedx anticipates adjusted net sales to increase by 10% or more in 2021, but this is contingent on the ability to sell micronized, particulate, and umbilical cord products. There is also an expected three-fold increase in research and development expenses and a significant decline in investigation, restatement and related expenses.
Positive Outlook
- Adjusted net sales are expected to increase by 10% or more in 2021.
- A significant decline in investigation, restatement and related expenses is expected in 2021.
- Company plans to file additional INDs
- Company continues working towards the filing of Biological License Applications
- Company assumes no restrictions on its ability to access hospitals, healthcare provider facilities and other places where products are sold.
Challenges Ahead
- FDA may determine that certain products do not qualify for regulation as human cells, tissues, and cellular and tissue-based products.
- The removal of micronized and particulate products from the market could negatively impact 2021 adjusted net sales by $20 million to $25 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...